SubsidieMeestersA disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach
TUMAGOSTIC aims to advance CP-506, a targeted Hypoxia Activated Prodrug, through clinical trials to improve cancer treatment efficacy and patient outcomes, with commercialization potential exceeding €450M.
Projectdetails
Introduction
TUMAGOSTIC will advance the development of CP-506, a next-generation Hypoxia Activated Prodrug (HAP) for the treatment of hypoxic tumours, representing over 50% of all solid tumours.
Overcoming Limitations
CP-506 overcomes the limitations of previous HAP development attempts and can provide more targeted treatment compared with alternatives such as chemo-immunotherapy combination and PARPi.
Innovative Approach
Our approach combines CP-506 with improved patient targeting based on two AI-driven biomarkers:
- Tumour hypoxia
- Homologous Recombination Defect
This strategy has high potential to increase the effectiveness of standard of care therapies such as immunotherapy (IO) in combination therapy (prodrug-IO) and improve patients’ progression-free survival and quality of life in several cancer types.
Commercialization Goals
We aim to advance CP-506 towards commercialization by carrying out a phase I-IIa clinical trial and corresponding business development activities. This will pave the way for a licensing agreement with the potential to exceed €450M.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.462.533 |
| Totale projectbegroting | € 3.517.905 |
Tijdlijn
| Startdatum | 1-1-2024 |
| Einddatum | 31-12-2025 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- CONVERT PHARMACEUTICALSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Reversing the advantage of cancers with Hypoxia and Homologous Recombination Defect (HRD) by using a pan-cancer, composite, lesions-specific biomarkerThis project aims to develop a validated software solution integrating hypoxia and HRD biomarkers to predict treatment outcomes for patients using the hypoxia-activated prodrug CP-506. | ERC POC | € 150.000 | 2022 | Details |
Catalysis for Cancer Treatment.Cat4CanCenter aims to develop innovative metal-based catalysts and lipid nanoparticle delivery systems to create effective therapies for glioblastoma, overcoming current treatment challenges. | ERC SyG | € 10.603.994 | 2024 | Details |
Targeting eicosanoid metabolism to overcome tumor immunosuppressionThis project aims to enhance cancer immunotherapy efficacy by targeting HPGDS in tumor-associated macrophages to reshape the immunosuppressive tumor microenvironment and improve patient outcomes. | ERC POC | € 150.000 | 2024 | Details |
PRodrug technology for Immunotherapy-priming via patient-friendly at-home MEtronomic dosingThe PRIME project aims to develop a novel prodrug platform for at-home metronomic dosing of chemotherapy to enhance immunotherapy efficacy in cancer treatment. | ERC POC | € 150.000 | 2023 | Details |
Reversing the advantage of cancers with Hypoxia and Homologous Recombination Defect (HRD) by using a pan-cancer, composite, lesions-specific biomarker
This project aims to develop a validated software solution integrating hypoxia and HRD biomarkers to predict treatment outcomes for patients using the hypoxia-activated prodrug CP-506.
Catalysis for Cancer Treatment.
Cat4CanCenter aims to develop innovative metal-based catalysts and lipid nanoparticle delivery systems to create effective therapies for glioblastoma, overcoming current treatment challenges.
Targeting eicosanoid metabolism to overcome tumor immunosuppression
This project aims to enhance cancer immunotherapy efficacy by targeting HPGDS in tumor-associated macrophages to reshape the immunosuppressive tumor microenvironment and improve patient outcomes.
PRodrug technology for Immunotherapy-priming via patient-friendly at-home MEtronomic dosing
The PRIME project aims to develop a novel prodrug platform for at-home metronomic dosing of chemotherapy to enhance immunotherapy efficacy in cancer treatment.